|
|||||
|
|
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma |
|
| Authors: | Daniel Reinhorn Michal Sarfaty Moshe Leshno Assaf Moore Victoria Neiman Eli Rosenbaum Daniel A. Goldstein |
| Affiliation: | 1. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel Contributed equally;2. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel;3. Coller School of Management, Tel Aviv University, Tel Aviv, Israel;4. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;5. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA |
| Abstract: | |
| Keywords: | Cost effectiveness Immunotherapy Programmed death 1 receptor Renal cell carcinoma Kidney cancer |